Walleye Capital’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Walleye Capital’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-800,000	Closed	-$28M	–	6228
2024 Q1	$28M	Buy	+800,000	New	+$29.2M	0.05%	278
2023 Q4	–	Sell	-70,850	Closed	-$1.3M	–	5834
2023 Q3	$1.3M	Buy	70,850 +37,744	+114%	+$790K	﹤0.01%	2064
2023 Q2	$859K	Sell	33,106 -119,746	-78%	-$2.8M	﹤0.01%	1979
2023 Q1	$2.88M	Sell	152,852 -54,130	-26%	-$1.26M	0.04%	520
2022 Q4	$5.1M	Buy	206,982 +97,166	+88%	+$2.86M	0.09%	261
2022 Q3	$1.97M	Buy	109,816 +41,678	+61%	+$751K	0.04%	564
2022 Q2	$773K	Sell	68,138 -42,394	-38%	-$624K	0.02%	782
2022 Q1	$2.46M	Buy	110,532 +54,999	+99%	+$1.4M	0.07%	313
2021 Q4	$2.42M	Buy	+55,533	New	+$2.22M	0.08%	287

Other funds holding INBX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Walleye Capital's INBX Position: Q2 2024 in Review

Walleye Capital sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 800,000 shares — an estimated $28M sold.

Walleye Capital first reported a position in INBX in Q4 2021 and held it in 9 quarters. The position peaked at $28M in Q1 2024. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

Walleye Capital reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Walleye Capital sold 800,000 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $28M.
Walleye Capital first reported a position in Inhibrx, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
Walleye Capital's Inhibrx, Inc. Common Stock position peaked at $28M in Q1 2024.
2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on Walleye Capital's 13F filing for Q2 2024, filed 14 Aug 2024.